Stille

Stille R&D Expenses

The Research & Development Expenses of Stille (STIL.ST) as of Nov 2, 2026 is 5.20 M SEK. In the previous year, Research & Development Expenses was 1.88 M SEK — a change of 176.82% (higher).

R&D Expenses

5.20 MSEK

YoY

176.82%

Last updated:

Research & Development Expenses of Stille is 2023 5.20 M SEK. Research & Development Expenses of Stille was 2022 1.88 M SEK. It decreases by 176.82% higher compared to the previous year.

The Stille R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2017
1.77 M SEK
Jan 1, 2018
1.75 M SEK
Jan 1, 2019
533,000.00 SEK
Jan 1, 2020
232,000.00 SEK
Jan 1, 2021
938,000.00 SEK
Jan 1, 2022
1.88 M SEK
Jan 1, 2023
5.20 M SEK
The Stille R&D Expenses history
YEARR&D ExpensesYoY
5.20 MSEK+176.82%
1.88 MSEK+100.11%
938,000.00SEK+304.31%
232,000.00SEK-56.47%
533,000.00SEK-69.61%
1.75 MSEK-0.74%
1.77 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stille Stock analysis

What does Stille do? Stille AB generates revenue by developing and selling medical equipment through two distinct business lines. The Surgery business area focuses on handcrafted, forged surgical instruments for open surgery, particularly in cardiovascular, reconstructive, and aesthetic plastic surgery. This segment produces essential tools such as scissors, forceps, artery forceps, needle holders, and clamps for medical professionals requiring precision instruments. The second revenue stream comes from the Patient Positioning area, which manufactures specialized procedure-specific tables. These devices are designed for cardiovascular surgery as well as gynecology, urology, and urodynamic examinations. By offering tailored positioning solutions for these specific medical fields, the company supports clinical procedures that require precise patient alignment. The company's operational structure includes wholly owned subsidiaries Stille Surgical Inc. and Stille Incentive AB, which support its manufacturing and distribution efforts. In 2013, the company adjusted its portfolio by selling its Sonesta business unit to ADDvise Lab Solutions publ AB, allowing it to focus on its core surgical and positioning equipment offerings. Stille is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stille stock

Research & Development Expenses of Stille is 5.20 M SEK in 2023.

Research & Development Expenses of Stille changed from 1.88 M SEK to 5.20 M SEK, representing a 176.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Stille since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Stille historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Stille

All Key Metrics — Stille